1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In

 
• By Bridget Silverman

Halozyme’s Enhanze technology has now brought seven monoclonal antibodies, including Ocrevus and Tecentriq, from IV to subcutaneous delivery, but Alteogen and other high-concentration formulation players hope to join the party as Medicare pricing issues help drive interest.

sparkling evergreen tree
With two recent approvals, subcutaneous conversions continue to sparkle as line extensions for established products. • Source: Shutterstock

The US FDA’s back-to-back approvals of Genentech’s Tecentriq Hybreza and Ocrevus Zunovo place a spotlight on biologics delivery specialist Halozyme Therapeutics, whose Enhanze technology has now brought subcutaneous dosing to seven monoclonal antibodies on the US market.

Key Takeaways

  • Halozyme extended its dominance of subcutaneous biologics delivery, with its Enhanze hyaluronidase platform used to convert seven IV antibodies to subcutaneous injection.

  • The most recent Enhanze approvals came on 12 and 13 September, for Genentech’s Tecentriq Hybreza and Ocrevus Zunovo

The Hybreza and Zunovo approvals, combined with BLAs under review for subcutaneous versions of Bristol Myers Squibb’s Opdivo (nivolumab) and Johnson & Johnson’s Rybrevant (amivantamab-vmjw), put Halozyme well on its way to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet

 
• By Bridget Silverman

The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.

More from Regulatory Trackers

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

Global Pharma Guidance Tracker - March 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.